SCHEMBL6774969

SCHEMBL6774969

CCC(C(=O)O)C(N)c1cc(Br)c(OC)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
APOBEC3A P31941 1/20 0.48
HTT P42858 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 2/20 0.41
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TPMT P51580 1/20 0.39
ACHE P22303 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
ATM Q13315 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780474 0.80 TTR (0.43) TSHRALDH1A1HPGDALOX15HSD17B10
Hydrochloric Acid SCHEMBL6783703 0.79 TTR (0.42) TSHRALDH1A1HPGDALOX15HSD17B10
SCHEMBL6777843 0.78 LCK (0.44) TSHRACHE
SCHEMBL6777007 0.78 TSHR (0.50) TSHRAPOBEC3AHTTAPOBEC3GNCOA1
SCHEMBL571771 0.77 TSHR (0.54) TSHRAPOBEC3AHTTAPOBEC3GSMN1; SMN2
SCHEMBL571770 0.77 TSHR (0.54) TSHRAPOBEC3AHTTAPOBEC3GSMN1; SMN2
SCHEMBL7836306 0.74 ALDH1A1 (0.46) TSHRAPOBEC3AHTTAPOBEC3GNCOA1
SCHEMBL6783358 0.73 ACHE (0.42) TSHRHTTSMN1; SMN2ALDH1A1ACHE
SCHEMBL6778049 0.71 FABP3 (0.43)
Hydrochloric Acid SCHEMBL6378948 0.70 TPMT (0.39) HTTSMN1; SMN2ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed